Cepharanthine as an effective small cell lung cancer inhibitor: integrated insights from network pharmacology, RNA sequencing, and experimental validation
Open Access
- 28 November 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1517386
Abstract
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options and poor prognosis, underscoring the need for new therapeutic agents.Methods: A library of 640 natural products was screened for anti-proliferative activity in SCLC cells. The effects of Cepharanthine (CE) on SCLC cells were assessed in vitro and in vivo. Network pharmacology and RNA sequencing (RNA-seq) were used to elucidate the molecular mechanisms. Pathway enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA) with Hallmark and Reactome gene sets. Protein-protein interaction (PPI) networks, along with the Cytoscape cytoHubba plugin, were used to identify key hub genes. RT-PCR and Western blotting were employed to validate mRNA and protein expression. Molecular docking studies assessed the binding affinity of CE to potential targets. Bioinformatics analyses, including expression profiling, prognostic evaluation, and loss-of-function studies, were used to explore the role of specific genes in SCLC.Results: CE was identified as a promising SCLC inhibitor. In vitro, CE significantly inhibited SCLC cell proliferation, colony formation, migration, and invasion, while promoting apoptosis. In vivo, CE treatment notably reduced tumor volume in xenograft models. Network pharmacology identified 60 potential target genes, with enrichment analysis indicating their involvement in cholesterol metabolism regulation. RNA-seq and experimental validation further confirmed that CE inhibits cholesterol synthesis in SCLC cells by downregulating key enzymes, including HMGCR, HMGCS1, IDI1, FDFT1, and SQLE. Molecular docking studies confirmed the binding of CE to these enzymes. Additionally, these enzymes were found to be highly expressed in SCLC cells, with elevated levels of HMGCS1, HMGCR, and IDI1 correlating with poor prognosis. Functional assays revealed that silencing these genes significantly suppressed SCLC cell proliferation.Conclusion: This study identifies CE as a potential therapeutic agent for SCLC, acting through the suppression of cholesterol synthesis, and uncovers novel therapeutic targets for the treatment of this aggressive cancer.Keywords
This publication has 34 references indexed in Scilit:
- Cepharanthine triggers ferroptosis through inhibition of NRF2 for robust ER stress against lung cancerEuropean Journal of Pharmacology, 2024
- Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cellsBiomedicine & Pharmacotherapy, 2024
- Targeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implicationsBiochemical Pharmacology, 2023
- Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formulaJournal of Ethnopharmacology, 2023
- Overcoming Chemotherapy Resistance in SCLCJournal of Thoracic Oncology, 2021
- Cholesterol metabolism: New functions and therapeutic approaches in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Cepharanthine ameliorates titanium particle-induced osteolysis by inhibiting osteoclastogenesis and modulating OPG/RANKL ratio in a murine modelBiochemical and Biophysical Research Communications, 2019
- Cepharanthine suppresses osteoclast formation by modulating the nuclear factor‐κB and nuclear factor of activated T‐cell signaling pathwaysJournal of Cellular Biochemistry, 2018
- Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancerCellular Signalling, 2018
- The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanismsChemico-Biological Interactions, 2017